RARE vs SRPT
RARE: Ultragenyx is a biopharmaceutical company dedicated to transforming the lives of patients suffering from rare and ultra-rare genetic diseases through innovative therapeutic development. SRPT: Sarepta Therapeutics is a leader in genetic medicine, specializing in innovative RNA-targeted and gene therapies to treat rare neuromuscular diseases like Duchenne muscular dystrophy.
Side-by-side fundamentals
| Metric | RARE | SRPT | Edge |
|---|---|---|---|
| Price as of 2026-10-21 close | $15.92 | $18.56 | |
| Market cap as of 2026-07-31 (share count; price 2026-10-21) | $1.6B | $2.0B | |
| Net margin FY2025, SEC XBRL | -85.4% | -32.5% | SRPT higher |
| Operating margin FY2025, SEC XBRL | -79.5% | -31.8% | SRPT higher |
| ROE FY2025, SEC XBRL | n/a | -62.5% | |
| ROA FY2025, SEC XBRL | -37.5% | -21.3% | SRPT higher |
| Debt / equity filed borrowings, leases excl., balance sheet 2026-06-30 | n/a | 0.55 | |
| Revenue growth (YoY) FY2025, SEC XBRL | +20.2% | +15.6% | RARE higher |
| Revenue CAGR (3y) SEC XBRL | +22.8% | +33.1% | SRPT higher |
| Dividend streak (yrs) SEC XBRL | 0 | 0 | Tie |
| Beta as of 2026-09-02 | 1.00 | 1.56 | |
| 1-year return as of 2026-10-21 close | -53.4% | -20.5% | SRPT higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.